尿液细胞因子水平作为健康成人AS01佐剂乙型肝炎疫苗免疫原性和反应原性预测指标的价值
研究纳入30名HBV未感染成人,检测接种AS01B佐剂乙型肝炎表面抗原疫苗后24种尿液细胞因子,与安慰剂注射后水平比较。多数尿液细胞因子检测受限,仅IP-10在第二剂接种后1天与全身反应原性强度评分显著相关(P=0.023),但与局部反应或抗体应答无关。尿液细胞因子作为血浆替代标志物的效用有限,IP-10的潜在价值需更大研究证实。
要点
- 多数尿液细胞因子在接种后无清晰变化,仅MCP-1和IP-10在多数受试者中出现短暂升高。
- 尿液IP-10在第二剂接种后1天与全身反应原性强度评分显著相关(P=0.023)。
- 尿液细胞因子与匹配血浆水平不相关,作为血浆替代标志物效用有限。
核心结论
- 多数尿液细胞因子作为血浆细胞因子的替代指标来预测AS01B佐剂疫苗的炎症反应、免疫原性或反应原性的效用有限,IP-10可能例外。
- 尿液IP-10作为全身疫苗反应原性潜在补充生物标志物的效用需在更大规模研究中证实。
研究设计与样本
- 研究纳入30名HBV未感染健康成人,接种AS01B佐剂乙型肝炎表面抗原疫苗(NCT01777295)。
- 在同一受试者首次接种前1个月给予单次安慰剂(生理盐水)注射,比较第二剂接种后尿液细胞因子水平与安慰剂后水平。
- 每次处理前及处理后1周内共8个时间点采集尿液,尿液浓度经肌酐水平标准化。
- 尿液细胞因子水平与既往报告的同受试者匹配血浆水平、局部和全身反应原性评分及抗体应答幅度配对分析。
主要发现
- 24种尿液细胞因子中仅少数可检测到:IL-8、IL-18和IL-6受体在接种后与安慰剂后相比无明显变化。
- MCP-1(CCL2)和IP-10(CXCL10)在多数受试者中显示接种后短暂升高。
- 尿液细胞因子水平与匹配的血浆水平不相关。
- 第二剂接种后1天尿液IP-10水平与同期全身反应原性强度评分显著相关(P=0.023),但与局部反应原性评分或抗体应答峰值无显著相关。
- MCP-1未检测到显著相关性。
局限性
- 尿液IP-10作为全身疫苗反应原性潜在补充生物标志物的效用需在更大规模研究中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Plasma cytokines are useful indicators of the inflammatory response to vaccination, and can serve as potential biomarkers of the systemic reactogenicity and immunogenicity of vaccines. Measurement of cytokines in urine may represent a non-invasive alternative to the blood-based markers. To evaluate whether urinary cytokine levels can help predict vaccine responses to an AS01B-adjuvanted vaccine, we measured concentrations of 24 cytokines in the urine from 30 hepatitis B virus (HBV)-naïve adults following administration of AS01B-adjuvanted HBV surface antigen vaccine (NCT01777295). Levels post-dose 2 were compared with the levels measured following a single placebo (saline) injection, which was administered 1 month before the first vaccination in the same participants. Urine was collected at eight timepoints before or up to 1 week following each treatment. Urinary concentrations were normalized to creatinine levels, and paired with previously reported, participant-matched plasma levels, local and systemic reactogenicity scores, and antibody response magnitudes. Of the urine cytokine panel, only few analytes were detectable: IL-8, IL-18 and IL-6 receptor, each showing no clear changes after vaccination as compared to placebo administration, and MCP-1 (CCL2) and IP-10 (CXCL10), which displayed in most participants transient surges post-vaccination. Urine levels did not correlate with the matched plasma levels. Interestingly, urinary IP-10 levels at 1 day post-second vaccination were significantly correlated (P = 0.023) with the concurrent intensity scores of systemic reactogenicity, though not with the local reactogenicity scores or peak antibody responses. No significant correlations were detected for MCP-1. Altogether, most urinary cytokines have limited utility as a proxy for plasma cytokines to help predict the inflammatory response, the immunogenicity or the reactogenicity of AS01B-adjuvanted vaccine, with the possible exception of IP-10. The utility of urinary IP-10 as a potential complementary biomarker of systemic vaccine reactogenicity needs substantiation in larger studies.
引用
- Burny W, Hervé C, Caubet M, et al. Utility of urinary cytokine levels as predictors of the immunogenicity and reactogenicity of AS01-adjuvanted hepatitis B vaccine in healthy adults. Vaccine. 2022. PMID: 35367070. doi:10.1016/j.vaccine.2022.03.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。